Nicha Boonpattrawong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicha Boonpattrawong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Manish Patankar
Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, 53705, USA
47 shared publications - Chien-Wei Wang
Department of Chemistry, University of Kansas, Lawrence, KS 66047, USA
45 shared publications - Naviya Schuster-Little
Department of Chemistry, University of Kansas, Lawrence, KS, USA
45 shared publications - Simon D. Weaver
Department of Biological Sciences, University of Notre Dame
45 shared publications - Rebecca J. Whelan
Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA
44 shared publications - Alexa R. Heaton
Morgridge Institute for Research, Madison, WI; University of Wisconsin, Department of Biomedical Engineering, Madison WI; University of Wisconsin, Department of Human Oncology, Madison WI
2 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2628-2632
Atovaquone-induced therapeutic rewiring of melanoma metabolism
- 24 March 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2628-2632
Open AccessAtovaquone-induced therapeutic rewiring of melanoma metabolism
- Open Access
Atovaquone-induced therapeutic rewiring of melanoma metabolism
Melanoma continues to be the deadliest form of skin cancer, emphasizing the need for new therapeutic strategies. Targeting tumor metabolism, particularly oxidative phosphorylation (OXPHOS) has emerged as a promising approach due its role in melanoma tumor survival, metastasis, and treatment resistance. In this study, we investigate the metabolic and antitumor effects of atovaquone, an FDA-approved and safe OXPHOS inhibitor that has not been previously tested in melanoma. We show that atovaquone rapidly and effectively inhibits OXPHOS and impairs glycolysis in melanoma, leading to metabolic reprogramming observed via metabolic imaging and marked depletion in energy (ATP) stores. Atovaquone also induces oxidative stress, evidenced by increased reactive oxygen species levels, DNA damage, and upregulation of antioxidant proteins. Moreover, atovaquone reduced melanoma cell viability and migration in vitro , and slowed tumor growth in vivo . Notably, these effects were observed in both BRAF -wild-type and mutant melanoma models, suggesting its potential as an effective treatment across different subtypes. Our study identifies atovaquone as a metabolic disruptor with antitumor activity against melanoma, supporting further investigation as a repurposed therapeutic strategy.
Open AccessAtovaquone-induced therapeutic rewiring of melanoma metabolism
Melanoma continues to be the deadliest form of skin cancer, emphasizing the need for new therapeutic strategies. Targeting tumor metabolism, particularly oxidative phosphorylation (OXPHOS) has emerged as a promising approach due its role in melanoma tumor survival, metastasis, and treatment resistance. In this study, we investigate the metabolic and antitumor effects of atovaquone, an FDA-approved and safe OXPHOS inhibitor that has not been previously tested in melanoma. We show that atovaquone rapidly and effectively inhibits OXPHOS and impairs glycolysis in melanoma, leading to metabolic reprogramming observed via metabolic imaging and marked depletion in energy (ATP) stores. Atovaquone also induces oxidative stress, evidenced by increased reactive oxygen species levels, DNA damage, and upregulation of antioxidant proteins. Moreover, atovaquone reduced melanoma cell viability and migration in vitro , and slowed tumor growth in vivo . Notably, these effects were observed in both BRAF -wild-type and mutant melanoma models, suggesting its potential as an effective treatment across different subtypes. Our study identifies atovaquone as a metabolic disruptor with antitumor activity against melanoma, supporting further investigation as a repurposed therapeutic strategy.
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Comparison of the sequence reported in this study to the sequence reported by O’Brien and co-workers (AF414442.2). Tandem repeats were aligned using Clustal Omega and visualized using Jalview with the Clustal Omega standard color scheme. Tandem repeats are shown in pairs, with AF414442.2 above and our reported sequence below. The consensus sequence shows abundance of each amino acid at each position.
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Comparison of the sequence reported in this study to the sequence reported by O’Brien and co-workers (AF414442.2). Tandem repeats were aligned using Clustal Omega and visualized using Jalview with the Clustal Omega standard color scheme. Tandem repeats are shown in pairs, with AF414442.2 above and our reported sequence below. The consensus sequence shows abundance of each amino acid at each position.
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
The amino acid consensus sequence derived from long-read cDNA sequencing of six sources of MUC16 mRNA
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
The amino acid consensus sequence derived from long-read cDNA sequencing of six sources of MUC16 mRNA
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Nanopore sequencing dot plots. The sequencing dot plots show the read length and average read quality. Each dot represents a single read. (A) Kuramochi, (B) OVCAR3, (C) OVCAR5, (D) OV1, (E) OV2, (F) OV3. Note that the axes for each plot are optimized for that plot’s data.
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Nanopore sequencing dot plots. The sequencing dot plots show the read length and average read quality. Each dot represents a single read. (A) Kuramochi, (B) OVCAR3, (C) OVCAR5, (D) OV1, (E) OV2, (F) OV3. Note that the axes for each plot are optimized for that plot’s data.
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Document 1 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
R script used for proteomics data analysis
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Document 1 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
R script used for proteomics data analysis
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Schematic models of MUC16. Top, The model derived from the sequence determined by O'Brien and colleagues (2001) containing 63 units in the tandem repeat domain. Bottom, The model proposed in this study, containing 19 units in the tandem repeat domain. The repeats that are not included in the proposed model (6, 10, and 12 through 53) are shown as white circles. Ellipses represent repeats that are not shown for clarity. The N-terminal domain is much larger than shown here and is also compressed for clarity.
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Schematic models of MUC16. Top, The model derived from the sequence determined by O'Brien and colleagues (2001) containing 63 units in the tandem repeat domain. Bottom, The model proposed in this study, containing 19 units in the tandem repeat domain. The repeats that are not included in the proposed model (6, 10, and 12 through 53) are shown as white circles. Ellipses represent repeats that are not shown for clarity. The N-terminal domain is much larger than shown here and is also compressed for clarity.
- Open Access
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Comparison of AlphaFold and I-TASSER predicted MUC16 tandem repeat model. The repeat 6 structure predicted by AlphaFold (brown) and I-TASSER (blue) are overlayed. The SEA domains predicted by the two algorithms show high similarity.
- 31 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Comparison of AlphaFold and I-TASSER predicted MUC16 tandem repeat model. The repeat 6 structure predicted by AlphaFold (brown) and I-TASSER (blue) are overlayed. The SEA domains predicted by the two algorithms show high similarity.